Sign In
23 Nov 2015 16:00
For immediate release 23 November 2013
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Directorate Change
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that Anthony Booley is to leave the Company to pursue other business interests. Anthony has been with Alliance for 17 years and has served on the Company's Board since the flotation in 2003. Peter Butterfield, who becomes Chief Commercial Officer, will begin to assume Anthony's responsibilities with immediate effect. Anthony will remain in his role until the handover is completed, which is anticipated to be by 31 March 2016.
John Dawson, Alliance Pharma's Chief Executive, commented: "On behalf of the Board, I would like to thank Anthony for his commitment and hard work over the 17 years that he has been at Alliance and for the significant contribution he has made to the Company's development. We wish him every success in his future ventures."
For further information:
Alliance Pharma plc | ||||
John Dawson, Chief Executive | + 44 (0) 1249 466966 | |||
Numis Securities Limited | ||||
Nominated Adviser: Michael Meade / Freddie Barnfield | + 44 (0) 20 7260 1000 | |||
Corporate Broking: David Poutney / James Black | ||||
Buchanan | ||||
Mark Court / Sophie Cowles / Jane Glover | + 44 (0) 20 7466 5000 | |||
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Follow the stocks
